Field flow fractionation of proteins, macromolecules and nanoparticles
The Postnova AF2000 MultiFlow reported to offer more flexibility, better performance and more robust results than any system before.
The Postnova AF2000 MultiFlow is a high performance Flow Field-Flow Fractionation (FFF) platform for separation of proteins, macromolecules and nanoparticles.
Modular in design, the AF2000 MultiFlow incorporates the combined experience, expertise and technological advances from Postnova Analytics' nearly two decades of leadership in FFF. Incorporating a range of FFF modules in a single integrated system to provide universal separation, the AF2000 MultiFlow offers more flexibility, better performance and more robust results than any system before.
The AF2000 MultiFlow platform is based on the Flow FFF principles using a unique crossflow field design in which samples are separated by their dynamic diffusion on the basis of molar mass or particle size. Because of this design and the absence of any stationary phase, field-flow fractionation on the AF2000 MultiFlow can be performed without exerting shear forces and stress on the molecules or particles being separated.
The AF2000 can be run with different eluents, wide ranging temperature conditions and the same system can be used for running planar Asymmetric Flow FFF (AF4) or circular Hollow Fiber Flow FFF separations (HF5). Consequently, the AF2000 MultiFlow is an ideal platform for the characterization of proteins, antibodies, aggregates, vaccines, VLPs, liposomes, nanoparticles and natural or synthetic polymers.
The AF2000 MultiFlow is available in a series of different models. Various add-on modules, extra options and special FFF detectors are available, such as Multi-Angle Light Scattering (MALS) and Dynamic Light Scattering (DLS). All Postnova FFF modules and detectors have been especially developed for FFF and are perfectly optimised not only for the use with the AF2000 MultiFlow, but also for the other Postnova FFF systems. Additionally, the AF2000 Series has been designed for easy interfacing with high-end detection technologies, such as ICP-MS, from other suppliers that may already be at use in laboratories.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance